Cas:27262-48-2 Levobupivacaine hydrochloride manufacturer & supplier

Chemical Name:Levobupivacaine hydrochloride

CAS.NO:27262-48-2

Synonyms:levobupivacaine monohydrochloride;Levobupivacainehydrochloride;(S)-(-)-BUPIVACAINE HCL;Levobupivacaine Hydrochloride;L-BUPIVACAINE HYDROCHLORIDE;L-(-)-Bupivacaine;(S)-Bupivacaine hydrochloride;(RS)-bupivacaine hydrochloride;BUPIVACAINE HCL;Levobupivacaine HCl;bupivacaine.hydrochloride;MFCD01704265;(-)-Bupivacaine hydrochloride;Chirocaine;(2S)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride (1:1);2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (2S)-, hydrochloride (1:1);1-butyl-piperidine-2-carboxylic acid-(2,6-dimethyl-anilide),hydrochloride;LEVAMISOLHCLSALT;(2S)-1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide hydrochloride (1:1);(S)-(-)-Bupivacaine hydrochloride;(S)-Bupivacaine;(-)-Bupicaine Hydrochloride;bupicainehydrochloride(-);Levobupivacaine (hydrochloride)

Molecular Formula:C₁₈H₂₉ClN₂O

Molecular Weight:324.889

HS Code:2942000000

Physical and Chemical Properties:

Melting point:254 °C (dec.)(lit.)

Boiling point:423.4ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:23.55000

Exact Mass:324.196838

LogP:4.74080

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 2811 6.1/PG 2

Packing Group:

Contact us for information like levobupivacaine monohydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Levobupivacaine (hydrochloride) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-butyl-piperidine-2-carboxylic acid-(2,6-dimethyl-anilide),hydrochloride Use and application,(S)-Bupivacaine technical grade,usp/ep/jp grade.

Related News: AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. Levobupivacaine hydrochloride manufacturer Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). Levobupivacaine hydrochloride supplier AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. Levobupivacaine hydrochloride vendor Domestic API companies cooperate with major international companies through commissioned processing, patent transfer, and joint venture production. Levobupivacaine hydrochloride factory Among 30,000 volunteers — all of them from either the United States or Mexico — vaccinated people were completely protected against severe and even moderate cases of illness.